article thumbnail

Impact of C-Reactive Protein, LDL Cholesterol, and Lipoprotein(a) on Long-Term Cardiovascular Risk in Women

NEJM Journal Watch - Cardiology

During 30 years of follow-up, all three biomarkers significantly and independently predicted incidence of a major adverse cardiovascular event in women.

article thumbnail

Cholesterol Crystal Dissolution Rate of Serum Predicts Outcomes in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Journal of the American Heart Association

BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. The resulting cholesterol crystals activate the NLRP3 (NOD‐like receptor protein 3) inflammasome, leading to inflammation and cardiovascular diseases. per 100 person‐years,P=0.01).

article thumbnail

New study shows glycan sugar coating of IgG immunoglobulin can predict cardiovascular health

Medical Xpress - Cardiology

When people hear about predicting heart disease, most will think of cholesterol levels.

article thumbnail

Marea Therapeutics’ Cardiometabolic Mission

CardiacWire

Marea Therapeutics emerged this week , announcing $190M in Series A/B funding and a mission to develop “a new generation of medicines for cardiometabolic diseases” – starting with their drug candidate targeting remnant cholesterol. Marea got its start from a tweet by UCSF cardiologist Ethan J.

article thumbnail

Abstract TMP119: Evaluation of Cognitive Function and Plasma Biomarkers in a Microemboli-Based VCID Model in Rats: Applying Clinical Recommendations From MarkVCID and the Lacunar Intervention Trial-2 (LACI-2) to a Preclinical Model

Stroke Journal

At 7-8 weeks after diabetes onset, control and diabetic rats were treated with ISMN/CZL for 4 weeks, then injected with cholesterol crystal ME and behavioral outcomes were monitored longitudinally for 16 weeks. Some of the biomarkers were unchanged (Table).

article thumbnail

Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study

Frontiers in Cardiovascular Medicine

Introduction Studies in cholesterol-fed rabbits showed that anti-proliferative chemotherapeutic agents such as paclitaxel associated with solid lipid nanoparticles (LDE) have marked anti-atherosclerotic effects. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment.

article thumbnail

Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer

Heart BMJ

Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. 58% had total cholesterol >5.0 All participants had normal LVEF prior to, and on completion of, treatment. Left ventricular systolic dysfunction (LVSD) was defined as LVEF <50%. years (range 5.9–10.8 –61.2).

Cancer 52